MicroRNAs in inflammatory bowel disease-pathogenesis,diagnostics and therapeutics  

作　　者：Mehmet Coskun Jacob Tveiten Bjerrum Jakob Benedict Seidelin Ole Haagen Nielsen 

机构地区：[1]Department of Gastroenterology,Medical Section 54 O3,University of Copenhagen,Herlev Hospital,DK-2730 Herlev,Denmark [2]Department of Cellular and Molecular Medicine,the Panum Institute,University of Copenhagen,DK-2200 Copenhagen N,Denmark [3]Department of Internal Medicine I,University of Copenhagen,Bispebjerg Hospital,DK-2400 Copenhagen NV,Denmark

出　　处：《World Journal of Gastroenterology》2012年第34期4629-4634,共6页世界胃肠病学杂志（英文版）

基　　金：Supported by Grants from Fonden til Lgevidenskabens Fremme(the AP Mller Foundation);the Family Erichsen Memorial Foundation;the Lundbeck Foundation;the Axel Muusfeldts Foundation;the Foundation of Aase and Ejnar Danielsen

摘　　要：The pathogenesis of inflammatory bowel disease (IBD) is complex and largely unknown. Until recently, research has focused on the study of protein regulators in inflammation to reveal the cellular and molecular networks in the pathogenesis of IBD. However, in the last few years, new and promising insights have been generated from studies describing an association between an altered expression of a specific class of non-coding RNAs, called microRNAs (miRs or miRNAs) and IBD. The short (approximately 22 nucleotides), endogenous, single-stranded RNAs are evolutionary conserved inanimals and plants, and regulate specific target mRNAs at the post-transcriptional level. MiRNAs are involved in several biological processes, including development, cell differentiation, proliferation and apoptosis. Furthermore, it is estimated that miRNAs may be responsible for regulating the expression of nearly one-third of the genes in the human genome. Thus, miRNA deregulation often results in an impaired cellular function, and a disturbance of downstream gene regulation and signaling cascades, suggesting their implication in disease etiology. Despite the identification of more than 1900 mature human miRNAs, very little is known about their biological functions and functional targets. Recent studies have identified dysregulated miRNAs in tissue samples of IBD patients and have demonstrated similar differences in circulating miRNAs in the serum of IBD patients. Thus, there is great promise that miRNAs will aid in the early diagnosis of IBD, and in the development of personalized therapies. Here, we provide a short review of the current state-of-the-art of miRNAs in IBD pathogenesis, diagnostics and therapeutics.The pathogenesis of inflammatory bowel disease （IBD） is complex and largely unknown. Until recently, research has focused on the study of protein regulators in inflammation to reveal the cellular and molecular networks in the pathogenesis of IBD. However, in the last few years, new and promising insights have been generated from studies describing an association between an altered expression of a specific class of non-coding RNAs, called microRNAs （miRs or miRNAs） and IBD. The short （approximately 22 nucleotides）, endogenous, single-stranded RNAs are evolutionary conserved inanimals and plants, and regulate specific target mRNAs at the post-transcriptional level. MiRNAs are involved in several biological processes, including development, cell differentiation, proliferation and apoptosis. Furthermore, it is estimated that miRNAs may be responsible for regulating the expression of nearly one-third of the genes in the human genome. Thus, miRNA deregulation often results in an impaired cellular function, and a disturbance of downstream gene regulation and signaling cascades, suggesting their implication in disease etiology. Despite the identification of more than 1900 mature human miRNAs, very little is known about their biological functions and functional targets. Recent studies have identified dysregulated miRNAs in tissue samples of IBD patients and have demonstrated similar differences in circulating miRNAs in the serum of IBD patients. Thus, there is great promise that miRNAs will aid in the early diagnosis of IBD, and in the development of personalized therapies. Here, we provide a short review of the current state-of-the-art of miRNAs in IBD pathogenesis, diagnostics and therapeutics.

关 键 词：Biomarker Crohn＇s disease DIAGNOSTICS In-flammatory bowel disease MicroRNA THERAPEUTICS Ulcer-ative colitis 

分 类 号：R574.62[医药卫生—消化系统]